Bioventure Partners’ Post

We’re excited to officially launch Jupiter Bioventures, a pioneering biotechnology venture foundry building bold, science-driven therapeutics companies. Co-Founders Nathaniel David, PhD, and Norman Sharpless, MD, bring decades of industry experience to drive a scalable foundry model, advancing #biotech innovation in #cancer and other areas in which insights from cancer biology provide insight. With $70 million raised from returning investors Mission BioCapital and Mayo Clinic alongside #lifescience investors Alexandria Venture Investments, Bioventure Partners, Cedars-Sinai Intellectual Property Company, CU Healthcare Innovation Fund, Eric Ball, Eshelman Ventures, LLC, Fox Ventures, The Brent and Julie Callinicos Trust and Vault Fund, Jupiter will found, launch, and operate multiple therapeutics companies. https://lnkd.in/eaUJsaE8 Stay tuned as we pursue breakthrough science to deliver #innovation in life sciences.

The pandemic was a challenging period for all. But it also offered us opportunities! The concept of Jupiter is a great example. Jupiter Bioventures, a product of virtual brainstorming with friends (Ned David, Ned Sharpless and Steve Tregay) to enable Mayo Clinic’s insatiable desire to create the next generation of Cures, is now a powerhouse of drug development that has attracted value-aligned investors and academic partners to join forces in the best interest of patients everywhere…. Congratulations Jupiter team! May the patients win….. Norman Sharpless Nathaniel David Steve Tregay Nirdesh K Gupta, PhD Steven VanNurden Peter Noseworthy, MD Vijay Shah Heidi Dieter Andy Danielsen Mayo Clinic Ventures James Rogers Clark Otley Olayemi (Yemi) Sokumbi, M.D. Pankaj Jay Pasricha Waleed Brinjikji Janani Reisenauer Justin Butler Geoff Johnson, MD, PhD Melissa Noel, MBA, MSE, Johannes Fruehauf, Owen Garrick, MD, Jeanette Caban Cheryl Willman, M.D. #venture, #biopharma, #capital, #venturecapital #accelerator, #drug #drugdevelopment, #development, #technology, #commercialization, #technologytransfer, #research, #clinicaltrial, #patient, #cure, #transform, #venturestudio, #disease, #cancer

Allink Biotherapeutics has successfully closed a $42M Series A round, led by Lanchi Ventures, with participation from YuanBio Venture Capital, Legend Capital, and C&D Emerging Industry Equity Investment, alongside Gaorong Ventures and Med-Fine Capital. Founded in 2023 by Hui Feng, AllinkBio is revolutionizing oncology and immunology with next-gen bispecific antibodies and ADCs. This funding will drive global clinical trials, pipeline expansion, and the company’s proprietary platform development. Stay ahead in the startup world! 🌟 Get a weekly digest of key happenings and insights delivered to your inbox every Monday morning. Don't miss out—subscribe now: https://lnkd.in/e4233YGN 🚀 #Biotechnology #Funding #Innovation #HealthTech

GEMMABio, a new biotherapeutics company founded by James M. Wilson, MD, PhD, has completed its seed round with investments from Double Point Ventures, Bioluminescence Ventures, Earlybird Venture Capital, and Bioculture Group (Savanne Life Sciences)! Read more here: https://lnkd.in/e6hh7q7t

Jupiter Bioventures, a San Francisco, CA-based biotechnology venture foundry that builds bold, science-driven therapeutics companies, announced closing a $70M initial financing. The syndicate includes co-founding investors Mission BioCapital and Mayo Clinic. New investors include Alexandria Venture Investments, Bioventure Partners, Cedars-Sinai Intellectual Property Company, CU Healthcare Innovation Fund, Eric Ball, Eshelman Ventures, Fox Ventures, The Brent and Julie Callinicos Trust, and Vault Fund. Proceeds from this financing will advance eight to ten companies developing therapeutics to treat cancer and other diseases where cancer biology provides insight. https://lnkd.in/gk7VwD25

🚀 We are thrilled to announce the successful closure of our €6.5 million funding round, led by Navigare Ventures, with strong support from existing shareholders Novalis Biotech and UU Invest, alongside other strategic investors. 🌟 This funding accelerates our mission to democratize nucleic acid mutation detection, advancing our technologies, operational capabilities, and commercialization strategy. Navigare Ventures highlighted Rarity Bioscience's breakthrough platform for nucleic acid sequence detection, emphasizing its high sensitivity and multiplex capability in healthcare, especially cancer research. “This investment will enable us to push the boundaries of innovation and bring our groundbreaking solutions to market faster,” said Linus Bosaeus, CEO of Rarity Bioscience. 💡 “We are excited to lead this funding round to support a team of innovators and entrepreneurs with world-leading ability to bring new molecular tools to the market,” said Alex Basu, Investment Manager at Navigare Ventures. 🧬 Support from UU Invest and Novalis Biotech also underscores Rarity Bioscience's leadership in genomics, bioinformatics, and personalized medicine. 🏥💊 "Having had the privilege to follow the Rarity team and technology for more than a year now made the investment decision very easy. I can only resonate with my own initial impression, extremely innovative and cool technology and a team with impressive pedigree and executional excellence," said Wim Van Criekinge, Co-founder & Managing Director of Novalis Biotech. With this funding, Alex Basu from Navigare Ventures and Jaroslav Belotserkovsky from Novalis Biotech will join our board, enhancing growth and governance. Stay tuned as we continue to innovate and transform healthcare with our pioneering technologies at Rarity Bioscience! 🌍💪 Read more on our website: https://lnkd.in/dWyaJJRY #RarityBioscience #HealthcareInnovation #FundingRound #NucleicAcidDetection #Genomics #Bioinformatics

...The Series B financing, which brought the total capital raised to approximately $200m, was led by RA Capital Management, with participation from new investors Qatar Investment Authority (QIA), Surveyor Capital (a Citadel company), #SheatreeCapital, Black Opal Ventures, Keller Williams Realty, Alexandria Ventures, LLC , and other undisclosed investors, and existing investors ARTIS Ventures, Playground Global, Bristol Myers Squibb, Abstract Ventures, Civilization Ventures, Mubadala Capital, Breton Capital Ventures, Washington Research Foundation (WRF) Capital, and Sahsen Ventures, LLC Ventures. Jake Simson, PhD, Partner at RA Capital Management has been appointed to the company’s Board of Directors. Led by Marc Lajoie, PhD, Co-Founder & Chief Executive Officer, Outpace Bio is advancing an internal pipeline of engineered T cell therapies for the treatment of solid tumors.... #seriesB #solidtumors #200m #SeriesB144m #tcelltherapies #capital #celltherapy #cellandgenetherapy #CarT #regenerativemedicine #advancedtherapies #investment #AIpoweredproteindesign #AI #cellprogramming #biotech #biotechnology #pipeline #oncology #cancer #lifescience #lifesciences #therapeutics

Hong Kong based ORI Capital recently final closed their second fund, ORI Fund II. 💸 $260 Million total commitments for Second Life Sciences Fund 💡 Growth-oriented venture investments into early-stage #biotech companies in the areas of #diagnostics, #drugdelivery, and #therapeutics focused on the disease areas with the highest mortality rates: cancer, cardiovascular and neurodegenerative diseases. 🌍 Globally 📈 Notable exits include: CG Oncology’s, Orchard Therapeutics - U.S. and TriSalus Life Sciences Nasdaq listings; and Semma Therapeutics which was acquired by Vertex in 2019 for $950 million in cash. Current portfolio companies include Pillar Biosciences Incorporated, AffyImmune Therapeutics and Enable Injections, Inc.. 💭 “We are in a golden-era of innovation across the intersection of #AI and biology, where technological breakthroughs are creating new approaches to diagnosing and treating disease” - Simone Song, Founding Partner, ORI Capital 🗞️By Business Wire https://lnkd.in/dZRgED2U 👏 For the #AudaciousInvestors unleashing innovation and empowering tomorrow🚀 Simone Song I Dicky To I Gang Song I Elaine Yang I Arnold Ching, I Danny Wong I Anthony S. I Nico Zheng I Sarah Oi Kwan Mak I Otto Cheung I Edward Tung I Team Ori … #venturecapital #vc #funds #startups #entrepreneurs #funding #tech #ai #entrepreneurship #technology #innovation #bigdata #hongkong #asia

J.P. Morgan Private Capital has successfully closed its inaugural fund, amassing $500 million to invest in pioneering biotech startups. This substantial fund will adopt a flexible and agnostic approach without constraints regarding the target companies' stage, location, or focus areas. However, the fund plans to make 20 to 25 early-stage investments, strategically targeting startups in cardiometabolic disease, immunology, oncology, and genetic medicine. With this dedicated fund, J.P. Morgan Private Capital aims to catalyze innovation and drive transformative advancements in these critical healthcare domains, fostering the development of groundbreaking therapies and solutions that could potentially improve countless lives. https://lnkd.in/gNQ9Anvv

🚀 Exciting News in the Biotech Sphere! 🚀 In an impressive stride for cancer therapy innovation, Clasp Therapeutics announced its launch this Wednesday, boasting a formidable $150 million in Series A financing. Situated in the key biotech hubs of Cambridge, Massachusetts, and Rockville, Maryland, Clasp Therapeutics is embarking on a mission to revolutionize the landscape of cancer treatment. This startup is not just another name in the vast sea of biotech. With heavyweight investors like Novo Holdings, Third Rock Ventures, Catalio Capital Management, and support from the American Cancer Society’s philanthropic fund among others, Clasp stands out with its ambition to develop a portfolio of next-generation immunotherapies. These therapies are designed to be both personalized and readily available, targeting the most challenging tumors with precision and efficacy. At the helm of Clasp Therapeutics is CEO Robert Ross, a figure well-known in the oncology field for his leadership at Surface Oncology Inc. before its acquisition and his impactful work at bluebird bio. Under his guidance, Clasp is delving into the potential of T cell engagers (TCEs), an emerging and promising approach in cancer treatment. Unlike conventional methods, Clasp’s TCEs aim to minimize off-target effects by targeting peptides presented by specialized HLA molecules on cancer cells, thus enabling a more precise attack on tumors. This innovative approach offers the dual benefits of personalized therapy's efficacy with the convenience and quicker treatment times of off-the-shelf options. It's a game-changer in oncology, promising to bring Clasp’s pioneering candidates to the clinic soon for early proof-of-concept data. As the biotech landscape continues to evolve, Clasp Therapeutics is undoubtedly a company to watch, heralding a new era of cancer treatment with its groundbreaking work. #Biotech #Innovation #CancerTherapy #ClaspTherapeutics #Immunotherapy